The Carlyle Group Inc. (CG)
| Market Cap | 20.12B |
| Revenue (ttm) | 5.04B |
| Net Income (ttm) | 1.08B |
| Shares Out | 361.14M |
| EPS (ttm) | 2.94 |
| PE Ratio | 18.92 |
| Forward PE | 13.89 |
| Dividend | $1.40 (2.51%) |
| Ex-Dividend Date | May 19, 2025 |
| Volume | 1,753,786 |
| Open | 54.90 |
| Previous Close | 54.45 |
| Day's Range | 54.43 - 55.99 |
| 52-Week Range | 33.02 - 57.50 |
| Beta | 1.85 |
| Analysts | Hold |
| Price Target | 48.54 (-12.85%) |
| Earnings Date | Aug 4, 2025 |
About CG
The Carlyle Group Inc. is an investment firm specializing in direct and fund of fund investments. Within direct investments, it specializes in management-led/ Leveraged buyouts, privatizations, divestitures, strategic minority equity investments, structured credit, global distressed and corporate opportunities, small and middle market, equity private placements, consolidations and buildups, senior debt, mezzanine and leveraged finance, and venture and growth capital financings, seed/startup, early venture, emerging growth, turnaround, mid ventu... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for CG stock is "Hold." The 12-month stock price target is $48.54, which is a decrease of -12.85% from the latest price.
News
Carlyle to sell up to 10% stake in Piramal Pharma, Moneycontrol reports
Private equity firm Carlyle Group is preparing to offload up to a 10% stake in India's Piramal Pharma , online news portal Moneycontrol reported on Thursday, citing sources.
Acentra Health Earns Fourth Consecutive Recognition on the Washington Business Journal's Annual ‘Largest Private Companies' List
MCLEAN, Va., June 30, 2025 (GLOBE NEWSWIRE) -- Acentra Health, a technology and health solutions and services company dedicated to accelerating better outcomes for its government and commercial health...
Carlyle: Military Industrial Complex is a Boon to Productivity
The military industrial complex has pushed technology to continue to improve, and it is this defense-driven innovation that has given Silicon Valley its edge says Jeff Currie, Chief Strategy Officer o...
Carlyle's Private-Credit Arm Signs Up to $2 Billion Deal With Diversified Energy
The asset-backed financing deal will support acquisitions by the natural-gas producer.
Bonds no longer hedge stock market risk, says Carlyle's Jason Thomas
Jason Thomas, Carlyle head of global research and investment strategy, joins 'Squawk Box' to discuss the latest market trends following Washington's surprise strikes on Iran, state of the economy, the...
Triton, Carlyle weigh bids for Germany's REMA Tip Top, sources say
Private equity funds, including Carlyle and Triton, are weighing bids for Germany-based industrial equipment maker REMA Tip Top, which is exploring a possible sale, three people familiar with the matt...
Citi and Carlyle Reportedly Teaming to Fund FinTechs
Citigroup and Carlyle Group have reportedly joined forces to fund FinTech companies. [contact-form-7] As Bloomberg News reported Thursday (June 12), the companies have signed an agreement that lets th...
Carlyle teams up with Citi to invest in fintech lenders
Investment firm Carlyle Group has partnered with U.S. banking giant Citigroup to provide asset-backed financing to fintech lenders, the companies said on Thursday.
Carlyle investment boosts insurance brokerage Trucordia's valuation to $5.7 billion
Insurance brokerage firm Trucordia has secured a $1.3 billion investment from Carlyle through a deal that valued the company at $5.7 billion, it said on Wednesday.
Trucordia to Receive $1.3 Billion Strategic Investment from Carlyle
Transaction positions company for accelerated growth through improved capital structure and simplified governance LINDON, Utah and NEW YORK , June 4, 2025 /PRNewswire/ -- Trucordia today announced it ...
Carlyle Bets $1.3 Billion on Insurance Brokerage Trucordia
The firm's latest equity investment through its Credit Opportunities strategy values Trucordia at $5.7 billion.
Carlyle's AlpInvest raises $4.1 billion for ninth co-investment fund
AlpInvest Partners has raised $4.1 billion for its ninth co-investment fund, an executive at the unit of private equity group Carlyle said, showing continued appetite among investors for access to buy...
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies for severe genetic diseases, today announced the completion of its sale to funds managed by gl...
Carlyle and SK Capital Partners Announce Expiration of bluebird bio Tender Offer
WASHINGTON & NEW YORK--(BUSINESS WIRE)--Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings, L.P. (“Parent”) today announced that the tender offer comme...
Carlyle Group: Recurring Revenue Makes Shares Attractive
Carlyle Group offers value with shares 20% below highs, strong AUM growth, and a secure 3.2% dividend yield. Fee-based earnings are highly predictable, with $26B pending fee-earning AUM and credible 6...
Resonetics® Invests in Nitinol Gun Drilling Capabilities Through Purchase of Assets from Medical Component Specialists
Establishes nitinol input tube operation to support premium, implant-grade tubing initiative and strengthen supply chain resilience NASHUA, N.H. , May 19, 2025 /PRNewswire/ -- Resonetics® announced to...
Carlyle, SK Capital Partners and bluebird bio Provide Updated Tender Instructions
SOMERVILLE, Mass.--(BUSINESS WIRE)--As previously announced on May 14, 2025, Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”)...
Carlyle nears deal to sell Italian premium brand Twinset, sources say
U.S. private equity group Carlyle Group is expected to clinch in the coming days an accord to sell Italian fashion brand Twinset to local investment firms Borletti Group and Quadrivio, two sources clo...
Bluebird bio receives higher upfront offer from PE firms Carlyle, SK Capital
Bluebird bio and Carlyle Group and SK Capital Partners said on Wednesday that the private equity firms have offered $5 per share upfront to takeover the gene therapy maker.
Carlyle, SK Capital Partners and bluebird bio Amend Merger Agreement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”), Carlyle (NASDAQ: CG) (“Carlyle”) and SK Capital Partners, LP (“SK Capital”) today announced they have amended their ...
The Carlyle Group, Inc. (CG) Q1 2025 Earnings Call Transcript
The Carlyle Group, Inc. (NASDAQ:CG) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants Daniel Harris - Partner & Head, Public Investor Relations Harvey Schwartz - CEO & Dire...
Carlyle's profit climbs on fee growth, record assets under management
Global investment firm Carlyle Group posted a 5.6% growth in first-quarter profit on Thursday, helped by higher fees as its assets under management climbed to a record.
Carlyle's Jenkins Says Tariffs Are 'Temporary Noise'
Mark Jenkins, head of global credit at Carlyle Group, called the tariffs “temporary noise,” and said they're accelerating trends that had already begun post-Covid, like reshoring of supply chains and ...
Carlyle and SK Capital Receive All Required Regulatory Approvals to Complete the Acquisition of bluebird bio
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”), Carlyle (NASDAQ: CG) (“Carlyle”), SK Capital Partners, LP (“SK Capital”) and Beacon Parent Holdings...
Carlyle CEO Harvey Schwartz says actively looking for investments
Harvey Schwartz, CEO of the Carlyle Group, says his firm is actively seeking opportunities to deploy some of the firm's $80 billion in free capital into new investments.